Immage Biotherapeutics Corp Stock Probability of Future Stock Price Finishing Over 1.0E-4
| IMMG Stock | USD 0.0001 0.00 0.00% |
Immage Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immage Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immage Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Immage Biotherapeutics generated a negative expected return over the last 90 days | |
| Immage Biotherapeutics has some characteristics of a very speculative penny stock | |
| Immage Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| Immage Biotherapeutics Corp currently holds 514 in liabilities with Debt to Equity (D/E) ratio of 2.52, implying the company greatly relies on financing operations through barrowing. Immage Biotherapeutics has a current ratio of 0.81, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immage Biotherapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (216.48 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immage Biotherapeutics Corp currently holds about 53.69 K in cash with (215.82 K) of positive cash flow from operations. | |
| Immage Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 70.0% of Immage Biotherapeutics shares are held by company insiders | |
| Latest headline from news.google.com: SNSE Stock Surges To 21-Month High Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits |
Immage Biotherapeutics Technical Analysis
Immage Biotherapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Immage Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Immage Biotherapeutics Corp. In general, you should focus on analyzing Immage Stock price patterns and their correlations with different microeconomic environments and drivers.
Immage Biotherapeutics Predictive Forecast Models
Immage Biotherapeutics' time-series forecasting models is one of many Immage Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Immage Biotherapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Immage Biotherapeutics
Checking the ongoing alerts about Immage Biotherapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Immage Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Immage Biotherapeutics generated a negative expected return over the last 90 days | |
| Immage Biotherapeutics has some characteristics of a very speculative penny stock | |
| Immage Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| Immage Biotherapeutics Corp currently holds 514 in liabilities with Debt to Equity (D/E) ratio of 2.52, implying the company greatly relies on financing operations through barrowing. Immage Biotherapeutics has a current ratio of 0.81, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immage Biotherapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (216.48 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immage Biotherapeutics Corp currently holds about 53.69 K in cash with (215.82 K) of positive cash flow from operations. | |
| Immage Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 70.0% of Immage Biotherapeutics shares are held by company insiders | |
| Latest headline from news.google.com: SNSE Stock Surges To 21-Month High Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits |
Check out Immage Biotherapeutics Analysis, Immage Biotherapeutics Valuation, Immage Biotherapeutics Correlation, Immage Biotherapeutics Hype Analysis, Immage Biotherapeutics Volatility, Immage Biotherapeutics Price History as well as Immage Biotherapeutics Performance. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Can Biotechnology industry sustain growth momentum? Does Immage have expansion opportunities? Factors like these will boost the valuation of Immage Biotherapeutics. Market participants price Immage higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Immage Biotherapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Immage Biotherapeutics's market price often diverges from its book value, the accounting figure shown on Immage's balance sheet. Smart investors calculate Immage Biotherapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Immage Biotherapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Immage Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immage Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immage Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.